Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Leukemia|April 10, 2019
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myelomaYan Song, Paul M C Park, Lei Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivoTeru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.
British Journal of Haematology|September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implicationsKlaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
British Journal of Haematology|October 28, 2017
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study resultsAndrew Spencer, Simon Harrison, Jeffrey Zonder, et al.
Experimental Hematology|July 24, 2002
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cellsDeepak Gupta, Klaus Podar, Yu Tzu Tai, et al.
Cancer Research|October 30, 2003
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ron T Bronson, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaKlaus Podar, Giovanni Tonon, Martin Sattler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myelomaPierfrancesco Tassone, Paola Neri, Renate Burger, et al.
Cancer Research|December 3, 2004
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myelomaLaurence Catley, Yu-Tzu Tai, Reshma Shringarpure, et al.
Cancer Research|February 20, 2007
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myelomaKlaus Podar, Marc S Raab, Giovanni Tonon, et al.
Pageof 17